Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

MitoRx Therapeutics (MitoRx), a platform biotechnology company developing novel mitochondrial-targeted sulfide-donor therapeutics (mtH2SD) in obesity-related disorders and myopathies announces the ...

In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

Scientists have long considered ketones (a fundamental chemical class) and esters (molecules formed when an acid reacts with an alcohol) to be locked treasure chests of possibilities.

The stock market saw something incredible in 2024, with the “Magnificent 7” tech giants leading the charge and driving a huge ...

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

The UK's self-regulated system for disclosing payments from drug companies to healthcare professionals and organizations is ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...